Feb 16, 2017

Kalytera Therapeutics Completes Acquisition of Talent Biotechs

  • Lead program in Graft versus Host Disease (“GvHD”), a life-threatening condition that can occur following stem cell or bone marrow transplantation

  • Four Phase 2 clinical studies evaluating CBD in the prevention and treatment of GvHD

  • Orphan drug designations (“ODD”) granted in the U.S. and Europe

  • Advancing towards FDA Phase 2b clinical studies

VANCOUVER, British Columbia, Feb. 16, 2017 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX-V:KALY) (“Kalytera”) announced today that it has successfully completed the previously announced acquisition (the “Acquisition”) of Talent Biotechs Ltd. (“Talent”), strengthening Kalytera’s position as an emerging market leader in cannabidiol (“CBD”) pharmaceuticals. Talent is a privately held, Israeli-based company evaluating the use of CBD to prevent and treat Graft versus Host Disease (“GvHD”).

Jan 23, 2017

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (the "Company" or "Kalytera") is pleased to announce it has entered into an agreement pursuant to which a syndicate of agents (the "Agents") led by Clarus Securities Inc. ("Clarus"), and including Haywood Securities Inc. and Canaccord Genuity Corp., has agreed to act on behalf of the Company, on a "best efforts" agency basis, in connection with a brokered private placement (the "Offering") of up to 24,000,000 common shares (each a "Share"), at a price of per Share of $0.50 (the "Offering Price"), for aggregate gross proceeds of up to $12,000,000. http://www.marketwired.com/press-release/kalytera-therapeutics-inc-announces-private-placement-tsx-venture-kaly-2190153.htm

Jan 23, 2017

Seth Yakatan, CEO of Kalytera, a company developing synthetic CBD compounds focused on different diseases including Osteoporosis, Prader-Willi Syndrome, and Obesity says follow the letter of the law, expand to related businesses and if possible, do as his company has done:

“Turn to synthetic cannabinoids or small molecule derivatives, which could allow for similar results for medical patients and less overall risk for business owners given the federal illegality of cannabis.”


Dec 30, 2016

Kalytera Therapeutics, Inc. (formerly Santa Maria Petroleum Inc.) (the "Company") (NEX:SMQ.H) announces that, in connection with the conditional approval of the TSX Venture Exchange (the "TSXV") regarding the previously announced merger transaction (the "Transaction") with Kalytera Therapeutics, Inc. ("Kalytera") and certain other transactions related thereto, the filing statement of the Company dated December 30, 2016 (the "Filing Statement"), which describes the Transaction and certain other related transactions which have occurred or will occur prior to or in connection with, the Transaction, has been filed on SEDAR under the Company's profile at www.sedar.com. http://www.marketwired.com/press-release/kalytera-therapeutics-inc-formerly-santa-maria-petroleum-inc-announces-filing-filing-tsx-venture-smq.h-2185778.htm

Dec 27, 2016

If there’s any industry in the US that’s growing at a rate like that of the tech sector in the late ‘90s, it’s the cannabis space. 28 states now allow for the medical consumption of cannabis, eight of which allow for its use as a recreational substance, and there’s no sign that state-specific industries will slow down their rate of growth.​ https://www.equities.com/news/innovation-in-the-cannabis-industry

Dec 26, 2016

This year saw big election wins for marijuana in several states. In addition, Colorado crossed the $1 billion mark for annual marijuana sales. Now a new year is almost here and a new presidential administration for the cannabis industry to navigate. It's time to look ahead and see what's in store for the cannabis industry in 2017. http://www.forbes.com/sites/debraborchardt/2016/12/26/here-are-the-top-2017-predictions-for-the-marijuana-industry/#26e7e71f689a

Dec 20, 2016

It’s a prognosis patients never want to hear: “No successful treatment regimens have been devised.” That’s the American Migraine Foundation’s summary of an ailment known as New Daily Persistent Headache (NDPH). Since Jonathan Zaid was diagnosed with the rare condition in 2007 at age 14, he’s been prescribed more than 40 different drugs in a futile attempt to alleviate migraines so debilitating that he couldn’t concentrate or fall asleep at night. Then, in 2014, his physician shifted tactics and prescribed a surprising new medication that almost immediately improved Zaid’s quality of life — medical marijuana. http://www.ozy.com/fast-forward/the-new-wonder-drug-synthetic-cannabis/74514

Dec 17, 2016

JERUSALEM — Israeli scientists began their pioneering research to isolate the psychoactive ingredient in marijuana with a 10-pound stash seized by the Tel Aviv police. That effort, in the 1960s, helped propel Israel to the vanguard of research into the plant’s medicinal properties and lay the foundations for a medical marijuana industry. https://www.nytimes.com/2016/12/17/world/middleeast/israel-a-medical-marijuana-pioneer-is-eager-to-capitalize.html?_r=1

Dec 14, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Andrew L. Salzman, M.D. as Kalytera’s Chief Executive Officer. Dr. Salzman will also serve as Chief Medical Officer and as a member of Kalytera’s Board of Directors. https://kalytera.co/andrew-salzman-chief-executive-officer/

Dec 10, 2016

Despite its continuing hardline stance against marijuana, the US Drug Enforcement Agency (DEA) has shown some signs of relenting and this summer opened the door to allowing more farms to grow cannabis for official research purposes. That’s an important step forward that may change the potential marijuana has for medical treatment. Up to this point, researchers have had to depend on just one farm at the University of Mississippi to supply cannabis for all studies. https://www.theguardian.com/lifeandstyle/2016/dec/10/medical-marijuana-research-new-treatments

Dec 09, 2016

Therakine Ltd. announces the appointment of Mr. Steven B. Bettis as its Chief Executive Officer.
Mr. Bettis, who has been working with the company as a consultant for several months, brings 25 years of commercial and drug development experience to
TheraKine, and was formerly the President and Co-founder of Eyetech Inc. http://www.releasewire.com/press-releases/therakine-announces-new-chief-executive-officer-750118.htm

Nov 04, 2016

TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 9474715, which enables innovative methods for locally injectable sustained release formulations of biologic and small molecule drugs with high concentration and superior injectability. https://upticknewswire.com/therakine-patent-portfolio-for-sustained-release-of-injectable-drugs/

Nov 01, 2016

On November 8, constituents in nine states will vote on medical or recreational, known as adult use, marijuana laws in what could be the largest policy decision pot has faced since being outlawed by the U.S. government in 1937. In California particularly, legalizing recreational weed for adults (defined in California’s Prop. 64, the Adult Use of Marijuana Act, for people 21 years and older) will have ramifications beyond the state’s borders. That’s because California’s projected dual market of medical and recreational pot is larger than those of Colorado, Oregon, Washington and Alaska combined—the first four states to have legalized weed. http://www.playboy.com/articles/can-medical-and-recreational-weed-co-exist

Oct 21, 2016

FitLife Brands, Inc. ("FitLife") (OTCBB: FTLF), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (www.sirenlabs.com), CoreActive® (www.coreactivenutrition.com), Metis Nutrition™ (www.metisnutrition.com), iSatori™ (www.isatori.com), Energize (www.tryenergize.com), and BioGenetic Laboratories, (www.biogeneticlabs.com), today announced that Stephen Adele, CEO of iSatori and Chief Innovation Officer of FitLife Brands, has resigned from the Company. He will continue to serve on the Company's Board of Directors. http://ir.fitlifebrands.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82552&GoTopage=1&Category=2139&BzID=2232&G=861

Oct 12, 2016

Invion is pleased to invite Shareholders to the Company’s 2016 Annual General Meeting. http://inviongroup.com/annual-general-meeting-notice-of-meeting-and-proxy-form/

Oct 06, 2016

Santa Maria Petroleum Inc. (the "Company") (NEX:SMQ.H) is pleased to announce that it has entered into a non-binding letter of intent dated October 6, 2016 (the "Letter of Intent") in respect of a proposed arm's length merger transaction with Kalytera Therapeutics, Inc. ("Kalytera") that would result in a reverse takeover of the Company by Kalytera (the "Proposed Transaction"), subject to approval of the TSX Venture Exchange ("TSXV") to list the shares of the resulting entity (the "Resulting Issuer") on the TSXV, among other conditions. The Resulting Issuer will operate as a life sciences issuer continuing the business of Kalyterahttp://www.marketwired.com/press-release/santa-maria-announces-letter-intent-proposed-merger-with-kalytera-therapeutics-tsx-venture-smq.h-2164748.htm

Sep 30, 2016

FitLife Brands, Inc. ("FitLife") (OTCBB: FTLF), an international provider of innovative and proprietary nutritional supplements for health conscious consumers marketed under the brand names NDS Nutrition Products™ ("NDS") (www.ndsnutrition.com), PMD® (www.pmdsports.com), SirenLabs® (www.sirenlabs.com), CoreActive® (www.coreactivenutrition.com), Metis Nutrition™ (www.metisnutrition.com), iSatori™ (www.isatori.com), Energize (www.tryenergize.com), and BioGenetic Laboratories, (www.biogeneticlabs.com), today announced results for its fiscal third quarter ended September 30, 2016. http://ir.fitlifebrands.com/profiles/investor/ResLibraryView.asp?ResLibraryID=82698&GoTopage=1&Category=2139&BzID=2232&G=861

Sep 16, 2016

In many ways, Scott Greiper is what you’d expect of a New York finance guy. He’s confident, well-dressed and articulate. His face lights up when he’s talking about building capital or putting together a board. What separates Greiper from the rest of Wall Street’s brood, though, is the nature of assets he deals in. Greiper is president of Viridian Capital Advisors, a New York investment firm that specializes in legal cannabis companies. Viridian consults with cannabis-based companies and helps pair them up with investors. It has created the world’s first cannabis stock index, which tracks progress of the world’s 50 most viable publicly traded pot companies. http://www.laweekly.com/news/cannabis-companies-are-attracting-marijuana-investors-with-a-lot-of-green-7381782

Sep 07, 2016

Given its diverse pool of user effects ranging from “the munchies” to pain relief and seizure reduction, it’s safe to say cannabis does many things. But one of the somewhat lesser-known benefits of cannabis is its effect on bone health. http://extract.suntimes.com/news/10/153/22465/marijuana-bone-health-cannabis-next-big-thing-osteoporosis-treatment

Sep 07, 2016

In a new trend for the federally prohibited plant, drug research and development companies like Insys Therapeutics, GW Pharmaceuticals, and Kalytera Therapeutics are researching and developing cannabis into pharmaceutical drugs. But it’s the U.S. headquartered firms who historically lead the way in producing innovative molecules that become drugs, according to the MIT principles and practice of drug development. https://www.marijuanatimes.org/the-future-of-clinical-cannabis-part-1/

Aug 29, 2016

Earlier this month the Drug Enforcement Administration (DEA) announced it would open some doors for research into cannabis. http://www.nnbw.com/news/dea-marijuana-remains-a-schedule-i-controlled-substance/

Aug 26, 2016

San Francisco, CA -- (ReleaseWire) -- 08/26/2016 --TheraKine Ltd. today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 86310619, a key patent for its innovative sustained-release formulation of injectable drugs. http://www.releasewire.com/press-releases/therakine-receives-patent-for-formulation-method-that-enables-sustained-release-of-injectable-drug-718360.htm

Aug 20, 2016

When it comes to technological developments in the widely varied cannabis industry, some come about due to the natural instinct to innovate, and some come about as a necessity to adapt with the ever-changing landscape that is the medical and recreational cannabis space. Over the years, businesses, researchers, advocates, and everyone in between has had their crack at assisting in ushering in new technologies and practices. http://theleafonline.com/c/business/2016/08/cannabis-technology-helps-patients-society/

Aug 13, 2016

It’s a federal decision that could mean a sea change for the cannabis world. The Drug Enforcement Agency (DEA) released a new policy on Thursday morning that will, for the first time, supply quality cannabis to the world of American researchers. The new policy statement from the DEA (in consultation with NIDA and the FDA) outlines a new approach to the availability of medical grade marijuana for science. https://www.marijuanatimes.org/dea-paves-narrow-path-for-cannabis-research/

Aug 12, 2016

Supporters of cannabis legalization got a rare bit of good news from the Drug Enforcement Administration Thursday, as the government announced in the Federal Register that the DEA will expand the number of places allowed to grow marijuana for research purposes. The policy change will be used to study the value of cannabis for treating chronic pain and epilepsy, among other purposes. https://www.equities.com/news/cannabis-industry-leaders-respond-to-deas-refusal-to-remove-marijuana-as-schedule-i-drug

Aug 11, 2016

This November, California voters are expected to pass Proposition 64, the Adult Use of Marijuana Act, which will effectively make recreational pot use legal in the state. The policy shift could spawn a large and emergent market for marijuana tourism — a prospect that looks attractive to many, particularly given the state’s ongoing budgetary crises. While visions of sativa wine tasting and THC surf lessons may float through entrepreneurs' heads, some cannabis businesses in the Los Angeles area say they will be largely unaffected by the legalization of recreational marijuana. According to these business owners, economic growth and meaningful development will be largely inhibited so long as the federal Drug Enforcement Administration continues to categorize cannabis as Schedule I. http://www.laweekly.com/news/why-recreational-marijuana-may-not-benefit-cannabis-businesses-until-dea-rescheduling-7239494

Aug 11, 2016

It’s no longer a secret that the cannabis industry is growing in a big way. In a remarkably short amount of time, cannabis has already been fully legalized in five states and legitimized in 20 other states and the District of Columbia for medicinal purposes, with legalization likely in many other states in the coming months and years. Today, cannabis is an industry with the potential for multiple billions of dollars in growth. https://www.equities.com/news/cannabis-business-leaders-advice-for-entrepreneurs-and-investors

Aug 11, 2016

The government’s decision Thursday to allow more growers to produce marijuana for medical experimentation could pave the way for the end of the drug’s prohibition — eventually. http://www.marketwatch.com/story/dea-sends-medical-marijuana-back-for-more-research-2016-08-11

Aug 10, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has signed a research agreement with Shaare Zedek Medical Center to identify and characterize genetic abnormalities in persons with Prader-Willi syndrome (“PWS”) that may contribute to the development of low bone mineral density (“BMD”) and osteoporosis. https://kalytera.co/pws-genetic-markers-study/

Aug 03, 2016

LOS ANGELES, CA -- (Marketwired) -- 08/03/16 -- BioCorRx Inc. (OTC PINK: BICX) (the "Company"), developer of the BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program used in the treatment of alcohol and opioid addiction, announced today it has signed a Development, Commercialization and License Agreement with TheraKine Ltd. effective July 28, 2016 for exclusive worldwide rights, licenses and sublicensing to patented and patent pending TheraKine technology for sustained release medication delivery. The agreement is specific to the use of the technology to treat addictions using the medication, naltrexone. http://www.biocorrx.com/news-media/press-releases/detail/59/biocorrx-announces-license-agreement-with-therakine-ltd-to

Aug 01, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, announced at the IPWSO Conference the results of a new preclinical study that tested the skeletal effects of KAL671 in a Prader-Willi syndrome (“PWS”) animal model. The study was led by Dr. Yossi Tam, D.M.D, Ph.D., Head of the Obesity and Metabolism Laboratory at the Hebrew University of Jerusalem and a member of Kalytera’s Scientific Advisory Board. https://kalytera.co/kal671-pws-data/

Jul 29, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Robert Farrell as Kalytera’s President and Chief Financial Officer. https://kalytera.co/robert-farrell-appointment/

Jul 28, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Dr. Stuart Silverman, M.D., FACP, FACR, as Senior Vice President of Medical Affairs. Dr. Silverman will also continue to serve as Co-Chair of Kalytera’s Scientific Advisory Board. https://kalytera.co/stuart-silverman-appointment/

Jul 27, 2016

Kalytera Therapeutics, Inc., a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, today announced the appointment of Dr. Robert S. Langer to Kalytera’s Scientific Advisory Board. https://kalytera.co/kalytera-appoints-robert-s-langer-to-sab/

Jun 08, 2016

Synthetic marijuana, something that’s normally frowned upon, is set to turn the medical marijuana industry upside down in the next coming years thanks to Kalytera, a company developing a suite of non-psychoactive cannabinoids. http://sugarnugz.com/meet-the-company-looking-to-revolutionize-the-medical-marijuana-market/

Jun 06, 2016

Kalytera Therapeutics, Inc., (“Kalytera”) a pharmaceutical company developing a portfolio of proprietary cannabinoid and endocannabinoid-like medicines, has entered into a technology licensing agreement (the “Agreement”) with Delivra Corp. (TSXV: DVA) (“Delivra). https://kalytera.co/delivra-technology-license/

Apr 20, 2016

If approved by the Food and Drug Administration, GW Pharmaceuticals PLC’s cannabis-derived drug, which treats child epilepsy, would be the first of its kind in the U.S. http://www.marketwatch.com/story/five-things-to-know-about-what-could-be-americas-first-cannabis-derived-drug-2016-03-15

Apr 21, 2016

Investors who are choosing among the hundreds of businesses involved in the emerging, yet growing cannabis industry are often caught in a conundrum as to whether medical companies are a safer investment compared to recreational businesses. https://www.thestreet.com/story/13540402/1/making-the-right-budding-investment-medical-versus-recreational-cannabis-companies.html

Mar 31, 2016

Check out this great segment from Iltv.tv today!

Our co-founder and CEO Saul Kaye discusses some of the medical conditions we believe medical cannabis treats.

We would love to hear from you: What medical conditions do you think medical cannabis can treat?



Mar 29, 2016

Already a pioneer in high-tech and cutting-edge agriculture, Israel is starting to attract American companies looking to bring medical marijuana know-how to a booming market back home. http://www.reuters.com/article/us-israel-cannabis-idUSKCN0WV1KD 

Mar 28, 2016

When you think of cannabis and innovation, Israel likely doesn't come to mind. But as we've recently highlighted here on MERRY JANE, Israel is advanced when it comes to cannabis-related exploration. https://www.merryjane.com/news/israel-the-epicenter-of-cannabis-research-and-innovation

Mar 13, 2016

That admonition kicked off the first day of presentations and roundtables at Cannatech, a three-day conference on the marijuana industry held this past week in Israel. Instead of pot edibles, hundreds of attendees munched on pita sandwiches and Turkish bourekas. http://qz.com/637973/israel-wants-to-be-the-tech-hub-for-the-world-cannabis-industry/

Mar 09, 2016

On February 9, the FDA sent out a number of warning letters to companies that make and sell products containing cannabidiol (CBD), a type of cannabinoid found in marijuana. Some of the products that the FDA tested contained no CBD in them at all.

Mar 02, 2016

As public support for marijuana legalization continues to rise and after 23 states plus the District of Columbia legalized it for medical use, questions about how traditional health care plays a role in the industry are becoming more pressing. 


Mar 01, 2016

The U.S. Drug Enforcement Agency made a rare move in December, and it’s good news for those who hold FDA-approved cannabidiol (CBD) clinical trials and have learned their regulatory requirements will be eased. http://www.myvoicenation.com/promotions/viewEmailByDistLstDelivId/vmg-74774?

Please reload

Dec 30, 2015

There was speculation last week that the U.S. Drug Enforcement Administration might be on the verge of downgrading the Schedule I classification of the cannabis plant. Unfortunately, the end result proved the implications behind the rumors were somewhat overstated, as the agency simply moved to ease the restrictions surrounding one of the herb’s most infamous non-intoxicating compounds in an effort to abridge the research process for Big Pharma. http://hightimes.com/news/dea-eases-restrictions-on-cbd-research-to-benefit-big-pharma/

Dec 24, 2015